Hutchmed (China) Limited

HCM | HKEX

Overview

ISIN(s):: KYG4672N1198 (+1 more)
LEI:: 2138006X34YDQ6OBYE79
Country:: Hong Kong
Address:: LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Website:: https://www.hutch-med.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

No description available.

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

Date	Filing	Language	Size
2025-11-05 08:25	Regulatory News Service Enrollment Complete in SAFFRON Global Phase III	English	29.9 KB
2025-11-03 08:30	Regulatory News Service Updates from R&D Event	English	23.6 KB
2025-10-23 08:00	Regulatory News Service HUTCHMED Presents Data at AACR NCI EORTC	English	20.4 KB
2025-10-21 10:30	Remuneration Information Vesting of awards under Long Term Incentive Plan	English	41.6 KB
2025-10-14 10:30	Board/Management Information Appointment of Independent Non-executive Director	English	20.0 KB
2025-10-13 08:05	Earnings Release Data to be Presented at the 2025 ESMO Congress	English	23.1 KB
2025-10-02 08:00	Regulatory News Service HUTCHMED Highlights Data to be Presented at ESMO	English	32.5 KB
2025-09-30 10:30	Declaration of Voting Results & Voting Rights Announcements Total Voting Rights	English	13.3 KB
2025-08-26 08:00	Board/Management Information Directorate Change	English	17.9 KB
2025-08-20 08:00	Regulatory News Service HUTCHMED Completes Enrollment of Phase III Trial	English	29.1 KB
2025-08-07 13:00	Earnings Release 2025 Interim Results	English	141.5 KB
2025-07-03 10:30	Report Publication Announcement HUTCHMED to Announce 2025 Half-Year Results	English	12.1 KB
2025-06-30 10:30	Declaration of Voting Results & Voting Rights Announcements Total Voting Rights	English	12.4 KB
2025-06-30 10:30	Remuneration Information Blocklisting Six Monthly Return	English	25.1 KB
2025-06-30 10:30	Regulatory News Service China Approval based on Phase III SACHI Trial	English	29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

No data available

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Company	Country	Ticker
Alpha Cognition Inc. Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.	United States of America	ACOG
Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
ALX ONCOLOGY HOLDINGS INC Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.	United States of America	ALXO
Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ